Home › NDC Lookup › RxCUI directory › RxCUI 2731484

Aficamten 5 MG Oral Tablet [Myqorzo] — RxCUI 2731484

RxNorm drug concept · Semantic branded drug
RxCUI 2731484 Semantic branded drug · SBD ● Current RxNorm concept 4 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2731484
Official nameAficamten 5 MG Oral Tablet [Myqorzo]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asMyqorzo 5 MG Oral Tablet
FDA products mapped4
Package NDCs mapped4
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Aficamten: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats adults with symptomatic obstructive hypertrophic cardiomyopathy, where a thickened heart muscle partly blocks blood flow out of the heart. It is meant to improve your abi...
  • You take one tablet by mouth once a day. You can take it with or without food. Your doctor sets your dose based on your heart ultrasounds and how you feel, so follow their directio...
  • This medicine lowers the heart's squeezing strength and can cause heart failure. Echocardiograms before and during treatment let your doctor catch problems early and adjust your do...
  • Why do I need so many heart ultrasounds?
📖 Read our full Aficamten guide →

🕸️ Concept Web — How Aficamten 5 MG Oral Tablet [Myqorzo] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Aficamten 5 MG Oral Tablet [Myqorzo] RxCUI 2731484

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Aficamten 2731469
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Myqorzo 2731475
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Aficamten Oral Tablet 2731473
    • Aficamten Oral Product 2731471
    • Aficamten Pill 2731472
    • Aficamten Oral Tablet [Myqorzo] 2731479
    • Myqorzo Oral Product 2731477
    • Myqorzo Pill 2731478
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Aficamten 5 MG Oral Tablet SCD · 2731482
  • Aficamten 5 MG SCDC · 2731481
  • Aficamten Oral Tablet SCDF · 2731473
  • Aficamten Oral Product SCDG · 2731471
  • Aficamten Pill SCDG · 2731472

Brand-Name Concepts

  • Aficamten 5 MG [Myqorzo] SBDC · 2731483
  • Aficamten Oral Tablet [Myqorzo] SBDF · 2731479
  • Myqorzo Oral Product SBDG · 2731477
  • Myqorzo Pill SBDG · 2731478
  • Myqorzo BN · 2731475

📦 FDA Products & Package NDCs

4 products · 4 package NDCs
4 package NDCs map to RxCUI 2731484 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
82112-0105-30 30 TABLET, FILM COATED in 1 BOTTLE (82112-105-30) MYQORZO Cytokinetics Inc. 2026-01-12
82112-0110-30 30 TABLET, FILM COATED in 1 BOTTLE (82112-110-30) MYQORZO Cytokinetics Inc. 2026-01-12
82112-0115-30 30 TABLET, FILM COATED in 1 BOTTLE (82112-115-30) MYQORZO Cytokinetics Inc. 2026-01-12
82112-0120-30 30 TABLET, FILM COATED in 1 BOTTLE (82112-120-30) MYQORZO Cytokinetics Inc. 2026-01-12
Observed labelers: Cytokinetics Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.